PRGN-2012 uses a gorilla adenovirus vector to deliver gene therapy to elicit robust T-cell immunity specific to HPV 6 or 11. A second gene therapy candidate that spurs antigen-specific T cell ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

PRGN-2012 is an adenovirus vector-based gene therapy expected to induce immune responses against HPV 6 or 11 infected cells. Findings showed among those treated at the recommended PRGN-2012 dose ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Future Oncol. 2009;5(3):339-357. Clinical trials of oncolytic adenoviral gene therapy in ovarian cancer are due to commence shortly. They will proffer valuable data on toxicity and safety and the ...

Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience ... adeno-associated virus (AAV), adenovirus, and other viral vector types. OXB’s world-class ...

and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform. GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity ...